BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3028919)

  • 1. [131I antiferritin in the treatment of hepatoma and Hodgkin's disease].
    Cohen Y; Moroz H
    Harefuah; 1986 Dec; 111(11):398-9. PubMed ID: 3028919
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiferritin immunoglobulin therapy for treatment of hepatoma.
    Held J; McLaughlin P
    Oncol Nurs Forum; 1987; 14(5):27-31. PubMed ID: 2821514
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of radio-immunochemotherapy-using antiferritin antibody combined with anthracycline drugs on hepatocellular carcinoma cell].
    Une Y; Sato Y; Alam S; Nagabuchi E; Hata Y; Uchino J
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):161-3. PubMed ID: 8380685
    [No Abstract]   [Full Text] [Related]  

  • 4. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
    Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
    Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
    Hellman S
    J Clin Oncol; 1985 Dec; 3(12):1569. PubMed ID: 2999345
    [No Abstract]   [Full Text] [Related]  

  • 6. Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver.
    Leichner PK; Klein JL; Siegelman SS; Ettinger DS; Order SE
    Cancer Treat Rep; 1983; 67(7-8):647-58. PubMed ID: 6307515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
    Order SE; Stillwagon GB; Klein JL; Leichner PK; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K; Finney K
    J Clin Oncol; 1985 Dec; 3(12):1573-82. PubMed ID: 2415692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma.
    Yuen AR; Higgins JP; Baker R; Kamel OW; Warnke RA; Knox SJ
    Hum Pathol; 2003 Apr; 34(4):381-4. PubMed ID: 12733120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetry of 131I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry.
    Leichner PK; Klein JL; Garrison JB; Jenkins RE; Nickoloff EL; Ettinger DS; Order SE
    Int J Radiat Oncol Biol Phys; 1981 Mar; 7(3):323-33. PubMed ID: 6268576
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiferritin IgG antibody for isotopic cancer therapy.
    Order SE; Klein JL; Leichner PK
    Oncology; 1981; 38(3):154-60. PubMed ID: 6259569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 131I antiferritin breakthrough.
    Moertel CG
    J Clin Oncol; 1986 Apr; 4(4):608-9. PubMed ID: 3958772
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection of specific anti-antibodies in patients treated with radiolabeled antibody.
    Klein JL; Sandoz JW; Kopher KA; Leichner PK; Order SE
    Int J Radiat Oncol Biol Phys; 1986 Jun; 12(6):939-43. PubMed ID: 3013817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies.
    Order SE; Klein JL; Ettinger D; Alderson P; Siegelman S; Leichner P
    Int J Radiat Oncol Biol Phys; 1980 Jun; 6(6):703-10. PubMed ID: 6256319
    [No Abstract]   [Full Text] [Related]  

  • 14. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center.
    Abrams RA; Pajak TF; Haulk TL; Flam M; Asbell SO
    Cancer J Sci Am; 1998; 4(3):178-84. PubMed ID: 9612600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol (Br J Surg 2003; 90: 1379-1383).
    Rai R; Rai S
    Br J Surg; 2004 Mar; 91(3):373; author reply 373. PubMed ID: 14991642
    [No Abstract]   [Full Text] [Related]  

  • 16. Dosimetry and treatment planning in radioimmunotherapy.
    Leichner PK; Yang NC; Wessels BW; Hawkins WG; Order SE; Klein JL
    Front Radiat Ther Oncol; 1990; 24():109-20; discussion 121-2. PubMed ID: 2160407
    [No Abstract]   [Full Text] [Related]  

  • 17. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.
    Vriesendorp HM; Morton JD; Quadri SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5888s-5892s. PubMed ID: 7493365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma.
    Leichner PK; Yang NC; Frenkel TL; Loudenslager DM; Hawkins WG; Klein JL; Order SE
    Int J Radiat Oncol Biol Phys; 1988 May; 14(5):1033-42. PubMed ID: 2834309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoradiotherapy for primary nonresectable hepatocellular carcinoma.
    Sitzmann JV; Order SE
    Surg Clin North Am; 1989 Apr; 69(2):393-400. PubMed ID: 2538937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 90Yttrium antiferritin--a new therapeutic radiolabeled antibody.
    Order SE; Klein JL; Leichner PK; Frincke J; Lollo C; Carlo DJ
    Int J Radiat Oncol Biol Phys; 1986 Feb; 12(2):277-81. PubMed ID: 3005201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.